Table 2.
Comparison of key histopathological outcomes at the patient level for mpMRI-detected and mpMRI-undetected prostate cancer in PICTURE for all four cancer thresholds on transperineal template mapping biopsy a
| Characteristic | Cancer definition 1 |
Cancer definition 2 |
Gleason ≥ 3 + 4 |
Any cancer |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCaD | PCaU | Difference (95% CI) | PCaD | PCaU | Difference (95% CI) | PCaD | PCaU | Difference (95% CI) | PCaD | PCaU | Difference (95% CI) | |
| Sample size, % (n/N) | 97 (102/105) | 2.9 (3/105) | 94.1 (90–99) | 94 (160/171) | 6.4 (11/171) | 87.6 (82–92) | 95 (139/146) | 4.8 (7/146) | 90.2 (86–95) | 91 (195/215) | 9.3 (20/215) | 81.7 (76–87) |
| Overall GS, % (n/N) | p = 0.02 | p = 0.09 | p = 0.1 | p = 0.01 | ||||||||
| 3 + 3 | 8.8 (9/102) | 33 (1/3) | 24.2 (−29 to 78) | 13 (21/160) | 36 (4/11) | 23 (−5.7 to 52) | 0 (0/139) | 0 (0/7) | – | 29 (56/195) | 65 (13/20) | 36 (14–58) |
| 3 + 4 | 59 (60/102) | 33 (1/3) | 26 (−29 to 80) | 66 (106/160) | 55 (6/11) | 11 (−19 to 42) | 76 (106/139) | 86 (6/7) | 10 (−17 to 36) | 54 (106/195) | 30 (6/20) | 24 (3.1–56) |
| 3 + 5 | 0.98 (1/102) | 0 (0/5) | – | 0.63 (1/160) | 0 (0/11) | – | 0.72 (1/139) | 0 (0/7) | – | 14 (28/195) | 0 (0/20) | – |
| 4 + 3 | 27 (28/102) | 33 (1/3) | 6 (−48 to 60) | 18 (28/160) | 9.1 (1/11) | 8.9 (−9.6 to 26) | 20 (28/139) | 14 (1/7) | 6 (−21 to 33) | 0.51 (1/195) | 5 (1/20) | 4.5 (−5.1 to 14) |
| 4 + 4 | 2.9 (3/102) | 0 (0/3) | – | 1.9 (3/160) | 0 (0/11) | – | 2.2 (3/139) | 0 (0/7) | – | 1.5 (3/195) | 0 (0/20) | – |
| 5 + 4 | 0.98 (1/102) | 0 (0/3) | – | 0.63 (1/160) | 0 (0/11) | – | 0.72 (1/139) | 0 (0/7) | – | 0.51 (1/195) | 0 (0/20) | – |
| Overall MCCL, % (n/N) | p = 0.02 | p = 0.04 | p = 0.03 | p = 0.0009 | ||||||||
| 1–5 mm | 7.8 (8/102) | 33 (1/3) | 25.2 (−28 to 80) | 41 (66/160) | 82 (9/11) | 41 (17–65) | 39 (54/139) | 86 (6/7) | 47 (20–74) | 52 (101/195) | 90 (18/20) | 38 (23–53) |
| 6–10 mm | 75 (77/102) | 66 (2/3) | 9 (−45 to 63) | 48 (77/160) | 18 (2/11) | 30 (5.9–54) | 49 (68/139) | 14 (1/7) | 35 (7.4–62) | 39 (77/195) | 10 (2/20) | 29 (15–44) |
| 11–15 mm | 17 (17/102) | 0 (0/3) | – | 11 (17/160) | 0 (0/11) | – | 12 (17/139) | 0 (0/7) | – | 8.7 (17/195) | 0 (0/20) | – |
| Median MCCL, mm (IQR) | 8 (6–10) | 6 (2–6) | 2 (0–6) | 6 (4–8) | 5 (4–5) | 1 (0–3) | 6 (4–9) | 5 (3–5) | 1 (0–4) | 5 (3–8) | 3 (2–5) | 2 (1–3) |
CI = confidence interval; GS = Gleason score; IQR = interquartile range; MCCL = maximum cancer core length; PCaD = prostate cancer detected by mpMRI; PCaU = prostate cancer undetected by mpMRI.
a
Nonsuspicious mpMRI defined as Likert score 1–2.